Soligenix granted European patent for improved production of synthetic hypericin

Soligenix announced that the European Patent Office has granted the patent entitled “Systems and Methods for Producing Synthetic Hypericin”. The newly issued patent’s claims are directed to a novel, highly purified form of synthetic hypericin manufactured through a unique proprietary process. Synthetic hypericin is the active pharmaceutical ingredient in HyBryte, the company’s photodynamic therapy for the treatment of cutaneous T-cell lymphoma, set to initiate a confirmatory Phase 3 clinical trial before the end of the year. This new European granted patent is a related patent to one previously issued in the U.S. Both patents are expected to expire in 2036.